CMPX Profile
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of antibody-based therapeutics for oncology. Focused on addressing complex cancer treatments, the company is advancing several investigational therapies through clinical trials to target critical pathways involved in tumor progression and immune system modulation.
Compass Therapeutics' pipeline includes several notable product candidates. CTX-009 is a bispecific antibody designed to inhibit both Delta-like ligand 4/Notch and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are essential for angiogenesis and tumor vascularization. By targeting these pathways, CTX-009 aims to disrupt tumor blood supply and hinder cancer growth.
Another key candidate is CTX-471, an IgG4 monoclonal antibody that acts as an agonist of CD137, a receptor involved in enhancing T-cell immune responses. This therapy seeks to boost the body's immune system to more effectively target and destroy cancer cells. Additionally, CTX-8371 is a bispecific inhibitor that targets both PD-1 and PD-L1, aiming to overcome tumor-induced immune evasion and restore the immune system's ability to recognize and attack cancer cells.
Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics combines its innovative antibody engineering platform with a robust pipeline of targeted therapies. The company's commitment to advancing oncology treatments is driven by its goal of addressing unmet medical needs and improving patient outcomes in cancer care.
|
